Is this the first time one of your posts has been removed , It has happened to the best &very best of posters on this B .B. Welcome to the ( post removed )club . The majority of folk enjoy your feminine input & would be sadly miss if you abandon us , All will soon be forgiven !!!
Good posts chaps....the standard of admin is patchy at best, some absolutely scandalous posting across the boards. Frustrating share, but good comment b o b re the OSE /Simbec timescales.....
I guess for your post to be removed someone must have reported it and therefore can only assume you hit a nerve there. Must be difficult for Admin. but just lately have seen the most disgraceful posts on other bbs go unchecked. A quick look at posting history usually tells you all you need to know.
RE: 5 years on
appears my comments in relation to double identities and the same member ramping STG and NEW have been removed. One company now sitting at almost at a MC of 50% lower and the other suspended. Yet a 'new' member to LSE can suggest that this BoD's may be acting fraudulently. If I wore a red badge then I would be asking for a refund. Mind boggling hypocrisy. LSE is a site to feed the ego's of 10 bob millionaires and investors better placed at a roulette table. LSE feel free to remove my democratic right to freedom of speech. Better still, delete my account, no advantage to be gained being a member.
They are a French biotech. company. At roughly the same time IMM announced that Simbec-Orion had been appointed as CRO for the Lupuzor trial OSE Pharms also appointed Simbec to run their phase III oncology trial. The RNS for that OSE Pharma included a paragraph re. timelines and what happens next and perhaps did a much better job of managing shareholders expectations. I'm not sure whether the same timelines would apply to Immupharma but it would certainly make sense and explain this news void. This is what they had to say:- "Simbec-Orion has started the feasibility study for the planned study with international clinical experts and patient enrolment is planned for the second half of 2015. Simbec-Orion will be responsible for site selection, patient enrolment, clinical monitoring, data management, statistical analysis and regulatory affairs." http://www.investegate.co.uk/simbec-orion-grp-ld/rns/ose-pharma-collaboration-for-cancer-trial/201501291101174914D/
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.